Therefore, in this study, we carried out an in-depth analysis of the transcriptional signature of NRF2 in animal models of FTP-TDP-43 and ALS-TDP-43A315T as well as patient samples with sALS in order to confirm NRF2 as a pharmacological target for these diseases. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.